Trial document





This study has been imported from ClinicalTrials.gov without additional data checks.
drksid header

  DRKS00003639

Trial Description

start of 1:1-Block title

Title

A Randomized Phase III Study to Determine the Efficacy of a Taxane and Bevacizumab With or Without Capecitabine as First Line Chemotherapy in Patients With Metastatic Breast Cancer

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym

TABEA

end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial

[---]*

end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

The purpose of this study is to determine whether

- Paclitaxel and bevacizumab showed improved PFS compared to paclitaxel alone. Recent
results of the AVADO study report a similar result for the combination of docetaxel and
bevacizumab. The AVADO study furthermore confirmed the dose of 15 mg/kg BW of
bevacizumab.

- As in metastatic breast cancer (MBC) poly-chemotherapies are frequently used, regimens
with bevacizumab and at least 2 cytotoxic agents should be investigated.

- Docetaxel and capecitabine showed a benefit in PFS and survival. This combi- nation is
therefore a reasonable choice.

- Dose of capecitabine and docetaxel should be reduced to 1800 mg/m2 and 75 mg/m2 to
improve tolerability without compromising efficacy.

- Paclitaxel and capecitabine is well tolerated and showed a PFS of 10.3 months.

- Docetaxel 100 mg/m2 as monotherapy in MBC not very often used b/o toxicity. 75 mg/m2
much more accepted in daily practice. Better comparability with DBX, if both arms have
75mg/m2 docetaxel as assumed.

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

Primary Objective:

- To determine the Progression Free Survival (PFS) in patients with metastatic breast
cancer after treatment with taxane plus bevacizumab with (TXB) or without capecitabine (TB).

Secondary Objective(s):

- To determine the objective response rate in both arms.

- To determine the duration of response in both arms.

- To determine the Time to Progression (TTP) in both arms.

- To determine the clinical benefit defined as CR, PR, or stable disease ≥ 24 weeks in
both arms.

- To determine the overall survival rate 3 years after "Last Patient In".

- To determine PFS and TTP response rates in patient's ≥ age 65.

- To determine the toxicity and compliance in both arms.

- To determine the predictive value of serum markers such as VEGF.

end of 1:1-Block scientific synopsis
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00003639
  •   2012/04/30
  •   2010/09/10
  •   yes
  •   [---]*
  •   [---]*
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  •   2008-003997-17 
  •   NCT01200212  (ClinicalTrials.gov)
  •   GBG 43  (German Breast Group)
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   Breast Cancer
  •   C50 -  Malignant neoplasm of breast
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   Drug: Taxane, Avastin
  •   Drug: Taxane, Avastin, Xeloda
end of 1:N-Block interventions
start of 1:1-Block design

Characteristics

  •   Interventional
  •   [---]*
  •   Randomized controlled trial
  •   Open (masking not used)
  •   [---]*
  •   Active control
  •   Treatment
  •   Parallel
  •   III
  •   [---]*
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

- Progression free survival (PFS); time frame: 10 month; The PFS time is defined as time from randomization to locoregional or systemic recurrence, second malignancy or death due to any cause; censored observations will be the last date of: "death", "last tumor assessment", "last follow up date" or "last date in drug log"

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

- To determine the objective response rate in both arms; time frame: End of Study
- To determine the duration of response in both arms.; time frame: End of Study
- To determine the Time to Progression (TTP) in both arms.; time frame: End of Study
- To determine the clinical benefit defined as CR, PR, or stable disease ≥ 24 weeks in both arms.; time frame: End of Study
- To determine the overall survival rate 3 years after "Last Patient In".; time frame: End of Study
- To determine PFS and TTP response rates in patient's ≥ age 65.; time frame: End of Study
- To determine the toxicity and compliance in both arms.; time frame: End of Study
- To determine the predictive value of serum markers such as VEGF; time frame: End of Study

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   Germany
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

  •  
end of 1:n-Block recruitment locations
start of 1:1-Block recruitment

Recruitment

  •   [---]*
  •   2009/07/31
  •   432
  •   [---]*
  •   [---]*
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Both, male and female
  •   18   Years
  •   no maximum age
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

- ECOG performance status 0-2

- Histological confirmed carcinoma of the breast with no over expression of HER2

- Locally advanced or metastatic stage of disease not suitable for surgery or
radiotherapy alone

- Patients must have either measurable or non-measurable target lesions according to
RECIST criteria (phase III). Complete staging work-up within 4 weeks prior to
registration. All patients must have chest X-ray (PA and lateral), abdominal
ultrasound or CT scan or MRI, and bone scan. In case of positive bone scan, bone
X-ray is mandatory. Other tests may be per- formed as clinically indicated

- The following previous systemic treatment are eligible:

- (neo)adjuvant chemotherapy (except if capecitabine was included) However if
(neo)adjuvant chemotherapy was anthracycline based, the maximum cumulative dose of
prior anthracycline therapy must not exceed 360 mg/m2 for doxorubicin and 720 mg/m2
for epirubicin. If taxanes or capecitabine were part of (neo)adjuvant treatment, a
treatment-free interval of > 6 months is requested

- adjuvant endocrine therapy.

- palliative endocrine treatments

- treatment with bisphosphonates

- treatment with immunotherapies

- Patient has to be fully recovered from previous radiotherapy. At least one measurable
lesion must be completely outside the radiation field or there must be pathologic
proof of progressive disease

- Absolute neutrophil count ≥ 2000 cells/ul, platelet count ≥ 100,000 cells/ul.

- Bilirubin ≤ 1.5x the upper limit of normal for the institution (ULN); elevation of
transaminases and alkaline phosphatase <2.5x ULN or <5x ULN for patients with liver
metastases

- Creatinine ≤ 1,25x ULN or creatinin-clearance > 50 ml/min (according to Cockroft
Gault). Urine dipstick for proteinuria <2+. Patients discovered to have ≥2+
proteinuria on dipstick urinalysis should undergo a 24 hour urine collection and must
demonstrate ≤1 g of protein in 24 hours

- Negative pregnancy test (urine or serum) within 14 days prior to registration for all
women of childbearing potential

- Patients must be available and compliant for treatment and follow-up. Patients
registered on this trial must be treated and followed up at the participating or a
cooperating site

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

- Known hypersensitivity reaction to the compounds or incorporated substances or known
dihydropyrimidine dehydrogenase deficiency

- Previous chemotherapy for metastatic disease, concurrent immunotherapy or hormonal
therapy (antihormonal, contraceptive and/or replacement therapy). Bisphosphonates may
be continued

- Life expectancy of less than 3 months

- Serious intercurrent medical or psychiatric illness that may interfere with the
planned treatment (including AIDS and serious active infection).

- Known or suspected congestive heart failure (>NYHA I) and/or coronary heart disease,
angina pectoris requiring antianginal medication, previous history of myocardial
infarction, evidence of transmural infarction on ECG, un- or poorly controlled
arterial hypertension (i.e. BP >150/100 mmHg under treatment with two
antihypertensive drugs), rhythm abnormalities requiring permanent treatment,
clinically significant valvular heart disease-

- Currently active infection

- Active peptic ulcer, incomplete wound healing or unhealed bone fracture

- Previous thromboembolic events, known hemorrhagic diathesis, coagulopathy with
increased bleeding risk, or treatment with anticoagulants Current or recent (within
10 days of first dose of bevacizumab) use of acetylic acid (>325mg/day) or
clopidogrel (> 75mg/day)

- Disease significantly affecting gastrointestinal function, e.g. mal- absorption
syndrome, resection of the stomach or small bowel, ulcerative colitis; abdominal
fistula, gastrointestinal perforation or intra-abdominal abscess within 6 months of
enrolment

- Major surgery within the last 28 days or anticipation of the need for major surgery
during study treatment with bevacizumab. No minor surgeries including insertion of an
indwelling catheter within 24 h prior to randomization

- Parenchymal brain metastases, unless adequately controlled by surgery and/or
radiotherapy with complete resolution of symptoms and discontinuation of all steroids

- History of other malignancy within the last 5 years which could affect the diagnosis
or assessment or outcome of metastatic breast cancer

- Concurrent treatment with other experimental drugs; participation in another clinical
trial with any investigational drug within 30 days prior to study entry

- Treatment with sorivudine or derivates e.g. brivudine

- Pregnant or lactating patients. Patients of childbearing potential must implement
adequate non-hormonal contraceptive measures (barrier methods, intra uterine
contraceptive devices, sterilization) during study treatment

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses

Addresses

  • start of 1:1-Block address primary-sponsor
    • German Breast Group
    end of 1:1-Block address primary-sponsor
    start of 1:1-Block address contact primary-sponsor
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact primary-sponsor
  • start of 1:1-Block address scientific-contact
    • German Breast Group
    • Hans-Joachim Lück, Prof. Dr. 
    end of 1:1-Block address scientific-contact
    start of 1:1-Block address contact scientific-contact
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact scientific-contact
  • start of 1:1-Block address public-contact
    • German Breast Group
    • Hans-Joachim Lück, Prof. Dr. 
    end of 1:1-Block address public-contact
    start of 1:1-Block address contact public-contact
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact public-contact
end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • Bitte wenden Sie sich an den Sponsor / Please refer to primary sponsor
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact materialSupport
end of 1:n-Block material support
start of 1:1-Block state

Status

  •   Recruiting stopped after recruiting started
  •   2012/10/01
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

  • [---]*
end of 1:n-Block publications
The parameters in ClinicalTrials.gov and DRKS are not identical. Therefore the data import from ClinicalTrials.gov required adjustments. For full details please see the DRKS FAQs .
  •   6
  •   2013/10/20
* This entry means the parameter is not applicable or has not been set.